Traditionally, low-risk patients with myeloproliferative neoplasms (MPNs) are not given medication, but new data challenge that thinking, said Raajit Rampal, MD, PhD, hematologic oncologist, associate ...

Please provide your email address to receive an email when new articles are posted on . The trial was presented at Society of Hematologic Oncology’s Annual Meeting. “Combining bispecifics with ...